ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 3,120,000 shares, a growth of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily volume of 389,200 shares, the short-interest ratio is currently 8.0 days. Approximately 11.5% of the shares of the stock are short sold.

Insider Buying and Selling

In related news, CEO Jason Lettmann acquired 4,400 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average price of $11.31 per share, with a total value of $49,764.00. Following the acquisition, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the sale, the insider now owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jason Lettmann purchased 4,400 shares of the stock in a transaction on Thursday, March 14th. The stock was acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the acquisition, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The disclosure for this purchase can be found here. 50.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ALX Oncology

Several institutional investors and hedge funds have recently bought and sold shares of ALXO. Swiss National Bank grew its position in ALX Oncology by 8.5% during the 1st quarter. Swiss National Bank now owns 19,200 shares of the company’s stock worth $324,000 after acquiring an additional 1,500 shares during the last quarter. JPMorgan Chase & Co. grew its position in ALX Oncology by 21.6% during the 1st quarter. JPMorgan Chase & Co. now owns 19,237 shares of the company’s stock worth $326,000 after acquiring an additional 3,417 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of ALX Oncology by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 10,745 shares of the company’s stock worth $182,000 after buying an additional 3,965 shares during the last quarter. BlackRock Inc. grew its position in shares of ALX Oncology by 1.1% in the 1st quarter. BlackRock Inc. now owns 1,355,478 shares of the company’s stock worth $22,907,000 after buying an additional 14,907 shares during the last quarter. Finally, Federated Hermes Inc. bought a new stake in shares of ALX Oncology in the 1st quarter worth approximately $914,000. 97.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of ALX Oncology in a report on Wednesday, April 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $14.00 price objective (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.83.

ALX Oncology Price Performance

Shares of ALX Oncology stock opened at $14.49 on Wednesday. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $726.67 million, a PE ratio of -3.86 and a beta of 1.58. The business’s 50-day moving average price is $13.50 and its 200-day moving average price is $11.84. ALX Oncology has a 12 month low of $3.94 and a 12 month high of $17.42.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Sell-side analysts forecast that ALX Oncology will post -3.33 EPS for the current fiscal year.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.